| USD ($) $ in Millions | LTM | Dec 27, 2025 | Dec 28, 2024 | Dec 30, 2023 | Dec 31, 2022 | Dec 25, 2021 | Dec 26, 2020 | Dec 28, 2019 | Dec 29, 2018 | Dec 30, 2017 | Dec 31, 2016 | Dec 26, 2015 | Dec 27, 2014 | Dec 28, 2013 | Dec 29, 2012 | Dec 31, 2011 | Dec 25, 2010 | Dec 26, 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Activities | ||||||||||||||||||
Statement of Cash Flows [Abstract] | ||||||||||||||||||
Net income | $ 10,967 | $ 8,295 | $ 9,626 | $ 9,155 | ||||||||||||||
Depreciation and amortization | 3,667 | 3,451 | 3,160 | 2,948 | ||||||||||||||
Gain associated with the Juice Transaction | - | - | 0 | 0 | ||||||||||||||
Impairment and other charges | (14) | 1,946 | 714 | 1,230 | ||||||||||||||
Indirect tax impact | - | - | 218 | - | ||||||||||||||
Product recall-related impact | - | 0 | 187 | 136 | ||||||||||||||
Payments for product recall-related impact | - | (6) | (148) | - | ||||||||||||||
Operating lease right-of-use asset amortization | 769 | 727 | 655 | 570 | ||||||||||||||
Share-based compensation expense | 321 | 288 | 362 | 380 | ||||||||||||||
Restructuring Charges | 783 | 983 | 727 | 445 | ||||||||||||||
Cash payments for restructuring charges | (615) | (796) | (436) | (434) | ||||||||||||||
Charge related to the transaction with Tingyi | - | - | - | - | ||||||||||||||
Payments for restructuring and other charges related to Tingyi | - | - | - | - | ||||||||||||||
Restructuring and other charges related to the transaction with Tingyi | - | - | - | - | ||||||||||||||
Cash payments for restructuring and other charges related to the transaction with Tingyi | - | - | - | - | ||||||||||||||
Venezuela impairment charges | - | - | - | - | ||||||||||||||
Gain on previously held equity interests in PBG and PAS | - | - | - | - | ||||||||||||||
Asset write-off | - | - | - | - | ||||||||||||||
Venezuela remeasurement charge | - | - | - | - | ||||||||||||||
Excess tax benefits from share-based payment arrangements | - | - | - | - | ||||||||||||||
Pension and retiree medical plan expenses | 567 | 504 | 414 | 150 | ||||||||||||||
Pension and retiree medical plan contributions | (427) | (472) | (348) | (410) | ||||||||||||||
Bottling equity income, net of dividends | - | - | - | - | ||||||||||||||
Deferred income taxes and other tax charges and credits | 704 | 71 | (42) | (271) | ||||||||||||||
Tax expense related to the TCJ Act | - | - | 0 | 0 | ||||||||||||||
Tax expense/(benefit) related to the TCJ Act | - | - | - | - | ||||||||||||||
Net tax (benefit)/expense related to the TCJ Act | - | - | - | - | ||||||||||||||
Tax payments related to the TCJ Act | - | (772) | (579) | (309) | ||||||||||||||
Other net tax benefits related to international reorganizations | - | - | - | - | ||||||||||||||
Provisional net tax expense related to the TCJ Act | - | - | - | - | ||||||||||||||
Change in assets and liabilities [Abstract] | ||||||||||||||||||
Accounts and notes receivable | (957) | (580) | (138) | (793) | ||||||||||||||
Inventories | (289) | (150) | (314) | (261) | ||||||||||||||
Prepaid expenses and other current assets | 445 | 195 | 40 | (13) | ||||||||||||||
Accounts payable and other current liabilities | 612 | (677) | (1,161) | 420 | ||||||||||||||
Income taxes payable | (24) | (433) | (123) | 310 | ||||||||||||||
Other, net | (693) | (712) | (307) | 189 | ||||||||||||||
Net Cash Provided by Operating Activities | 14,569 | 12,087 | 12,507 | 13,442 | ||||||||||||||
Investing Activities | ||||||||||||||||||
Capital spending | (4,098) | (4,415) | (5,318) | (5,518) | ||||||||||||||
Sales of property, plant and equipment | 345 | 528 | 342 | 198 | ||||||||||||||
Acquisition of SodaStream, net of cash and cash equivalents acquired | - | - | - | - | ||||||||||||||
Cash payments related to the transaction with Tingyi | - | - | - | - | ||||||||||||||
Acquisitions of PBG and PAS, net of cash and cash equivalents acquired | - | - | - | - | ||||||||||||||
Acquisition of manufacturing and distribution rights from DPSG | - | - | - | - | ||||||||||||||
Investment in WBD | - | - | - | - | ||||||||||||||
Proceeds from finance assets | - | - | - | - | ||||||||||||||
Acquisitions, net of cash acquired, investments in noncontrolled affiliates and purchases of intangible and other assets | (3,391) | (3,391) | (256) | (314) | ||||||||||||||
Proceeds associated with the Juice Transaction | - | - | 0 | 0 | ||||||||||||||
Reduction of cash due to Venezuela deconsolidation | - | - | - | - | ||||||||||||||
Divestitures, sales of investments in noncontrolled affiliates and other assets | 39 | 39 | 166 | 75 | ||||||||||||||
Cash restricted for pending acquisitions | - | - | - | - | ||||||||||||||
Cash proceeds from sale of PBG and PAS stock | - | - | - | - | ||||||||||||||
Short-term investments, by original maturity: | ||||||||||||||||||
More than three months - purchases | (105) | (190) | (425) | (555) | ||||||||||||||
More than three months - maturities | 197 | 605 | 0 | 556 | ||||||||||||||
More than three months - Sales | 0 | 0 | 0 | 12 | ||||||||||||||
More than three months - sales | - | - | - | - | ||||||||||||||
Three months or less, net | (3) | 45 | 5 | 3 | ||||||||||||||
Other investing, net | (10) | (100) | 14 | 48 | ||||||||||||||
Net Cash Used for Investing Activities | (3,989) | (6,879) | (5,472) | (5,495) | ||||||||||||||
Financing Activities | ||||||||||||||||||
Proceeds from issuances of long-term debt | 2,988 | 8,189 | 4,042 | 5,482 | ||||||||||||||
Payments of long-term debt | (3,165) | (4,082) | (3,886) | (3,005) | ||||||||||||||
Debt redemptions | - | - | 0 | 0 | ||||||||||||||
Cash tender and exchange offers/debt redemptions | - | - | - | - | ||||||||||||||
Debt repurchase | - | - | - | - | ||||||||||||||
Short-term borrowings, by original maturity | ||||||||||||||||||
More than three months - proceeds | 5,425 | 6,391 | 5,786 | 5,428 | ||||||||||||||
More than three months - payments | (6,320) | (7,920) | (5,639) | (3,106) | ||||||||||||||
Three months or less, net | 2,090 | 1,170 | 392 | (29) | ||||||||||||||
Payments of acquisition-related contingent consideration | - | - | - | 0 | ||||||||||||||
Cash dividends paid | (7,881) | (7,638) | (7,229) | (6,682) | ||||||||||||||
Share repurchases - common | (987) | (1,000) | (1,000) | (1,000) | ||||||||||||||
Share repurchases - preferred | - | - | - | - | ||||||||||||||
Proceeds from exercises of stock options | 128 | 97 | 166 | 116 | ||||||||||||||
Withholding tax payments on restricted stock units (RSUs) and performance stock units (PSUs) converted | (97) | (113) | (135) | (140) | ||||||||||||||
Excess tax benefits from share-based payment arrangements | - | - | - | - | ||||||||||||||
Acquisition of noncontrolling interests | - | - | - | - | ||||||||||||||
Other financing | (56) | (73) | (53) | (73) | ||||||||||||||
Net Cash Used for Financing Activities | (7,875) | (4,979) | (7,556) | (3,009) | ||||||||||||||
Effect of exchange rate changes on cash and cash equivalents and restricted cash | (148) | 422 | (687) | (277) | ||||||||||||||
Effect of exchange rate changes on cash and cash equivalents and restricted cash | - | - | - | - | ||||||||||||||
Cash and Cash Equivalents, Period Increase (Decrease) | - | - | - | - | ||||||||||||||
Net Increase/(Decrease) in Cash and Cash Equivalents and Restricted Cash | 2,557 | 651 | (1,208) | 4,661 | ||||||||||||||
Acquisition and divestiture-related charges | (109) | 453 | - | 41 | ||||||||||||||
Inventory fair value adjustments and merger and integration costs | - | - | - | - | ||||||||||||||
Merger and integration costs | - | - | - | - | ||||||||||||||
Payments for Merger Related Costs | $ (172) | $ (228) | - | $ (41) |